7-{(4-Fluorophenyl)[(4-methylpyridin-2-yl)amino]methyl}quinolin-8-ol | 315239-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-{(4-Fluorophenyl)[(4-methylpyridin-2-yl)amino]methyl}quinolin-8-ol
• 英文别名: 7-[(4-fluorophenyl)-[(4-methylpyridin-2-yl)amino]methyl]quinolin-8-ol
• CAS: 315239-92-0
• 化学式: C₂₂H₁₈FN₃O
• 分子量: 359.403
• InChiKey: DNFFYAHWCDVOJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  58
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氨基-4-甲基吡啶 、 8-羟基喹啉 、 对氟苯甲醛 以 neat (no solvent) 为溶剂， 生成 7-{(4-Fluorophenyl)[(4-methylpyridin-2-yl)amino]methyl}quinolin-8-ol
  参考文献：
  名称：

  Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker

  摘要：

  Anti-apoptotic Bcl-2 family proteins are important oncology therapeutic targets. To date, BH3 mimetics that abrogate anti-apoptotic activity have largely been directed at Bcl-2 and/or Bcl-xL. One observed mechanism of resistance to these inhibitors is increased Mcl-1 levels in cells exposed to such therapeutics. For this reason, and because Mcl-1 is important in the onset of lymphoid, myeloid, and other cancers, it has become a target of great interest. However, small molecule inhibitors displaying potency and selectivity for Mcl-1 are lacking. Identifying such compounds has been challenging due to difficulties in translating the target selectivity observed at the biochemical level to the cellular level. Herein we report the results of an HTS strategy coupled with directed hit optimization. Compounds identified have selective Mcl-1 inhibitory activity with greater than 100-fold reduced affinity for Bcl-xL. The selectivity of these compounds at the cellular level was validated using BH3 profiling, a novel personalized diagnostic approach. This assay provides an important functional biomarker that allows for the characterization of cells based upon their dependencies on various anti-apoptotic Bcl-2 proteins. We demonstrate that cells dependent on Mcl-1 or Bcl-2/Bcl-xL for survival are commensurately responsive to compounds that genuinely target those proteins. The identification of compound 9 with uniquely validated and selective Mcl-1 inhibitory activity provides a valuable tool to those studying the intrinsic apoptosis pathway and highlights an important approach in the development of a first-in-class cancer therapeutic. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.08.017

文献信息

• METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT
  申请人：Errico Joseph P.

  公开号：US20110301193A1

  公开（公告）日：2011-12-08

  Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR.

  本文提供具有抗增殖作用的化合物。还提供一些化合物，可以调节由二聚化臂和域间系带组成的多域蛋白的活性，例如EGFR，其中未系带的延伸构象是活性状态，而系带的构象是非活性状态，导致自抑制构型。还提供了用于识别此类化合物的方法和药效团。其他方面提供了治疗增殖性疾病、疾病或病状的方法或治疗。例如与EGFR相关的疾病。
• COMPOSITIONS OF TARGETED DRUG DEVELOPMENT
  申请人：Errico Joseph P.

  公开号：US20140163069A1

  公开（公告）日：2014-06-12

  Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR.

  本文提供具有抗增殖效应的化合物。还提供了可以调节多域蛋白质活性的化合物，包括具有二聚化臂和域间系索的EGFR，其中无系索的伸展构象是活性状态，而系索的构象是非活性状态，导致自抑制构型。还提供了用于识别此类化合物的方法和药效团。其他方面提供了治疗增殖性疾病、疾病或病情的方法或治疗。例如与EGFR相关的疾病。
• METHODS OF TARGETED DRUG DEVELOPMENT
  申请人：Errico Joseph P.

  公开号：US20140194439A1

  公开（公告）日：2014-07-10

  Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR.

  本文提供了具有抗增殖作用的化合物。还提供了可以调节包括二聚化臂和域间连接的多域蛋白活性的化合物，例如EGFR，其中未连接的扩展构象是活性状态，连接的构象是非活性状态，导致自抑制构型。还提供了用于识别此类化合物的方法和药效团。其他方面提供了用于增殖性疾病、疾病或病情的方法或治疗，例如与EGFR相关的疾病。
• Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker
  作者：David J. Richard、Ryan Lena、Thomas Bannister、Noel Blake、William E. Pierceall、Nicole E. Carlson、Christina Eberhart Keller、Marcel Koenig、Yuanjun He、Dmitriy Minond、Jitendra Mishra、Michael Cameron、Timothy Spicer、Peter Hodder、Michael H. Cardone

  DOI：10.1016/j.bmc.2013.08.017

  日期：2013.11

  Anti-apoptotic Bcl-2 family proteins are important oncology therapeutic targets. To date, BH3 mimetics that abrogate anti-apoptotic activity have largely been directed at Bcl-2 and/or Bcl-xL. One observed mechanism of resistance to these inhibitors is increased Mcl-1 levels in cells exposed to such therapeutics. For this reason, and because Mcl-1 is important in the onset of lymphoid, myeloid, and other cancers, it has become a target of great interest. However, small molecule inhibitors displaying potency and selectivity for Mcl-1 are lacking. Identifying such compounds has been challenging due to difficulties in translating the target selectivity observed at the biochemical level to the cellular level. Herein we report the results of an HTS strategy coupled with directed hit optimization. Compounds identified have selective Mcl-1 inhibitory activity with greater than 100-fold reduced affinity for Bcl-xL. The selectivity of these compounds at the cellular level was validated using BH3 profiling, a novel personalized diagnostic approach. This assay provides an important functional biomarker that allows for the characterization of cells based upon their dependencies on various anti-apoptotic Bcl-2 proteins. We demonstrate that cells dependent on Mcl-1 or Bcl-2/Bcl-xL for survival are commensurately responsive to compounds that genuinely target those proteins. The identification of compound 9 with uniquely validated and selective Mcl-1 inhibitory activity provides a valuable tool to those studying the intrinsic apoptosis pathway and highlights an important approach in the development of a first-in-class cancer therapeutic. (C) 2013 Elsevier Ltd. All rights reserved.
• US9073858B2
  申请人：——

  公开号：US9073858B2

  公开（公告）日：2015-07-07